Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00988052 · ClinicalTrials.gov registry record · Phase 3
A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Terminated
- Registry status
- Phase 3
- Development phase
- 839
- Enrollment target
NCT00988052 is a Phase 3 study that was terminated before completion, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 839 participants.
The verdict
NCT00988052, a Phase 3 study, was terminated before completion, sponsored by Teva Branded Pharmaceutical Products R&D.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 839 participants
- Enrollment target
Study Summary
The purpose of this study is to make laquinimod 0.6 mg available for all subjects who completed the placebo-controlled MS-LAQ-301 study according to the protocol and to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis.
Interventions
- DRUG Laquinimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 839 participants |
| Start Date | 2009-11-10 |
| Est. Completion | 2017-07-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00988052
The ClinicalTrials.gov registry entry for NCT00988052 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 839 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Laquinimod is the first listed.
NCT00988052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00988052 about?
NCT00988052 is a clinical study titled "A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course". The purpose of this study is to make laquinimod 0.6 mg available for all subjects who completed the placebo-controlled MS-LAQ-301 study according to the protocol and to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing...
What is the current status of trial NCT00988052?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 839 participants. The study started on 2009-11-10. Estimated completion is 2017-07-01.
What interventions are being tested in trial NCT00988052?
The interventions under investigation include: Laquinimod (DRUG).
Who is sponsoring clinical trial NCT00988052?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.